Ceesay Abraham sold $93K of RAPP
Ceesay Abraham (Chief Executive Officer) sold 2,210 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $42.11 ($42.11–$42.74) across 2 trades on 2026-07-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the specific open-market sale size, price range, and that it was executed under a pre-arranged Rule 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but this particular disclosure is typically not a high-conviction fundamental catalyst.
What to watch
The filing does not indicate why the sale occurred (taxes, diversification, planned liquidity). Without additional context (e.g., other insider buys/sells, guidance, trial updates), the signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Rapport Therapeutics, Inc., reported by CEO Ceesay Abraham.
Ticker impact
CEO Ceesay Abraham sold 2,210 shares of Rapport Therapeutics on 2026-07-27 for about $93,060.86 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling. The disclosed dollar amount is modest relative to most public-company market caps, so impact is likely limited.
Market effects
Minimal. This is company-specific insider trading with no sector-wide regulatory or clinical catalyst mentioned.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider sales can still be interpreted by some traders as a lack of near-term conviction, especially in thinly traded small caps.
Key entities
- issuerRapport Therapeutics, Inc.
Company whose CEO reported an open-market sale of shares via SEC Form 4.
- insiderCeesay Abraham
CEO and director who sold 2,210 shares on 2026-07-27 under a 10b5-1 plan.
